A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Conditions:   Colorectal Cancer Metastatic;   Triple Negative Breast Cancer;   Non Small Cell Lung Cancer;   Bladder Cancer;   GastroEsophageal Cancer;   Renal Cell Carcinoma;   MSI-H Interventions:   Biological: EDP1503;   Biological: Pembrolizumab Sponsors:   Evelo Biosciences, Inc.;   SCRI Development Innovations, LLC;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials